Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

The Moderna vaccine is 94.5% effective against coronavirus, according to early data released Monday by the company, making it the second vaccine in the United States to have a stunningly high ...

A Boston-based nonprofit is among six organizations that on Monday filed a lawsuit against the U.S. Health and Human Services ...

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine ...

A head-to-head study of coronavirus vaccines in the United States finds the Moderna vaccine is slightly more effective than Pfizer’s in real-life use in keeping people out of the hospital, and J ...

The Moderna Covid-19 vaccine awaits administration at a vaccination clinic in Los Angeles, Dec. 15, 2021. AFP via Getty Images, FILE. Moderna's bid for FDA authorization for its two-dose vaccine ...

Moderna has received nearly $2.5 billion from U.S. taxpayers to develop, manufacture and distribute its vaccine; while Pfizer/BioNTech has been promised just under $2 billion for manufacturing and ...

Moderna announced on Nov. 16 that a preliminary analysis showed its experimental vaccine was nearly 95% effective in preventing the novel coronavirus.

Moderna, the maker of one of three COVID-19 vaccines currently authorized for use in the U.S., announced Tuesday it will start testing its vaccine on children as young as 6 months old.. The move ...